Biosimilar interchangeability and emerging treatment strategies for IBD

Biosimilars/Research | Posted 03/09/2021 post-comment0 Post your comment

Biosimilar development and utilization, as well as non-biological oral agents with unique pathological targets, will continue to dominate efforts to improve patient access and reduce the overall cost of care as non-surgical treatments for Crohn’s disease and ulcerative colitis in adults and children. Therapeutic drug monitoring, combined with inflammatory biomarkers, have become the standard of care to assess effectiveness.

05 AA011027

In his commentary, US researcher Richard Parrish summarizes a collection of key references published within the last 10 years, and identifies pharmacologic research directions to improve treatment access and success through greater use of biosimilars combined with other targeted small molecule agents that possess unique pathophysiologic mechanisms for inflammatory bowel disease (IBD) in adult and paediatric patients [1].

He found that while there is ample evidence to assert that biosimilars for infliximab and adalimumab are comparable to the reference product in moderate to severe IBD, slow uptake of biosimilar use may be due to lack of third-party insurance coverage for multiple reasons (including contractual reference product rebates to pharmacy benefit managers), patent disputes in court related to approved indications and reference product manufacturer market strategies that limit use.

Combinations of antitumour necrosis factor-alpha (anti-TNF-α) biosimilars with anti-adhesion, anti-integrin and interleukin 12/23 antagonists (more common in children than in adults), as well as Janus kinase inhibitors (tofacitinib, peficitinib, upadacitinib, filgotinib), sphingo-sine-1-phosphate [S1P] receptor modulators (ozanimod, etrasimod), phosphodiester-ase-4 inhibitors (apremilast), selective histone deacetylase 3 inhibitors (givinostat, vorinostat) and/or substitutions of phosphatidylcholine, i.e. agents with different mechanisms of action, are on research agendas in various phases and treatment horizons. The development of these non-biological small molecules that can be absorbed orally or affect the colonic lumen topically will be vital for the achievement of sustained clinical remission in adults and children.

Dr Parrish concluded that future research should quantify the relative contribution of each of these choices to overall treatment success. Patient and provider education and positive framing of non-medical switching strategies needs to be incorporated into organized programmes for both adult and paediatric populations, including parents and caregivers, so that the negative attribution towards biosimilar initiation or switching is minimized. Psychosocial issues often impact the development and progress of IBD and are best approached through a multidisciplinary approach. Early attention to growth and development in children is paramount to optimal physical and psychological well-being. Research to elucidate pharmacotherapies of choice for anxiety, depression and pain is needed in children and adults. Oral liquid formulations for children and those that cannot swallow non-biological oral solid dosage forms used in combination will be important for continued success in treating vulnerable patient populations.

Conflict of interest
The author of the research paper [1] declared that there was no conflict of interest.

Abstracted by Professor Richard H Parrish, Professor of Pharmacology, Department of Biomedical Sciences Mercer University School of Medicine, Macon, Georgia, USA.

Editor’s comment
Readers interested to learn more about biosimilar interchangeability are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

USA and Europe differ in interchangeability of biosimilars

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
1.9 – CiteScoreTracker 2021 (Last updated on 4 August 2021)

Submit a manuscript to GaBI Journal

Related articles
Different approaches to the interchangeability of biosimilars

International policies for interchangeability, switching and substitution of biosimilars

LATIN AMERICAN FORUM

The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Biosimilares e intercambiabilidad en oncología

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Biosimilares e intercambiabilidad en oncología

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

  
Reference
1. Parrish RH. Biosimilar interchangeability and emerging treatment strategies for inflammatory bowel diseases: a commentary. Gastroenterol Insights. 2021;12:293-301.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Clinical development of biosimilars in the oncology setting
Cancer image015
Biosimilars/Research Posted 17/09/2021
Knowledge and perceptions of naming for biosimilars in the US
Naming 1 V13I27
Biosimilars/Research Posted 10/09/2021
New quality-range-setting method for biosimilarity assessment
127 AA010925
Biosimilars/Research Posted 10/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010